To our knowledge, just one study has investigated the effects of a treatment based on ALA alone in PCOS patients: Masharani et al. administered alpha lipoic acid to six non-obese, nondiabetic patients with PCOS for a cycle of 16 weeks, showing a significant amelioration in insulin sensitivity and a notable decrease in triglyceride levels, demonstrating that ALA also exerts an anti-atherogenic effect [9]. The gene discussed is INS; the disease is polycystic ovary syndrome.